Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lisata TherapeuticsLSTA -2.40%32 EV-to-EBIT is 0.72 as of Jul. 30, 2026. GuruFocus rates LSTA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review. Among 384 Biotechnology companies, Lisata Therapeutics ranks better than 78.12% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lisata Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $32.31 Mil.
Lisata Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lisata Therapeutics EV-to-EBIT Related Terms
Lisata Therapeutics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Lisata Therapeutics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lisata Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lisata Therapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lisata Therapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lisata Therapeutics's EV-to-EBIT falls into.
Lisata Therapeutics's current Enterprise Value is $-12.53 Mil.
Lisata Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-17.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lisata Therapeutics (LSTA) has a EV-to-EBIT of 0.72 as of Jul. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lisata Therapeutics and its competitors. According to the industry distribution chart, Lisata Therapeutics ranks #84 out of 384 companies in the Biotechnology industry, placing it in the top 21.9%.
Is Lisata Therapeutics' EV-to-EBIT too high?
Lisata Therapeutics' current EV-to-EBIT is 0.72. The Biotechnology industry median EV-to-EBIT is 12.17. Lisata Therapeutics' value of 0.72 is 94.1% below this industry median. Based on the distribution chart, Lisata Therapeutics ranks #84 out of 384 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lisata Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Lisata Therapeutics' EV-to-EBIT compare to CYCN and OSRH?
According to the Biotechnology industry distribution chart, Lisata Therapeutics ranks #84 out of 384 companies for EV-to-EBIT. This places Lisata Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 12.17. Lisata Therapeutics' value of 0.72 is 94.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.17, based on 384 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lisata Therapeutics's current EV-to-EBIT of 0.72 is 94.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lisata Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lisata Therapeutics's current EV-to-EBIT is 0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lisata Therapeutics stock overvalued right now?
Lisata Therapeutics (LSTA) has a current EV-to-EBIT of 0.72. The current EV-to-EBIT is 0.72 and 94.1% below the Biotechnology industry median of 12.17. Lisata Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lisata Therapeutics (LSTA), the current EV-to-EBIT is 0.72 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.
32GF Score
Get the complete analysis for LSTA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSTA has been successfully added to your 
